
    
      This trial is aimed at evaluating the safety and effectiveness of PCV chemotherapy in
      patients with recurrent high-grade glioma with IDH1/2 mutation. And, this trial is approved
      by medical ethics committee of hebei yanda hospital. Also, the trial has got a registry code
      "ChiCTR-OOC-15005759" in China clinical trial registry. Researchers will conduct thsi trial
      from 2015/02 to 2017/12, and 100 recurrent high-grade glioma with IDH1/2 mutation patients
      will be recruited. Patients who are recruited will get PCV chemotherapy in ether Hebei Yanda
      Hospital or Beijing Tiantan hospital, and get follow-ups from clinicians.
    
  